A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.
TAG24 NEWS on MSN11m
Major study of weight-loss jabs shows slew of benefits but also risksHugely popular weight-loss jabs like Wegovy have been making headlines for enabling people to manage diabetes and excess weight along with other benefits, scientists say.Increasingly recommended by ...
The human body can’t make vitamin C, so we have to get it through diet or supplements. If you're taking supplements, here's ...
The gut microbiome, which seems to be affected by our diet, plays an important role in reducing the growth of potentially ...
Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...
Analyst David Lebowitz from Citi maintained a Buy rating on Exelixis (EXEL – Research Report) and keeping the price target at $38.00.Invest ...
Exelixis (EXEL) announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...
Norovirus—a highly contagious virus known for causing gastrointestinal distress—is making headlines this winter due to a ...
News Medical on MSN2d
Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patientsAbelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback